Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia
暂无分享,去创建一个
C. Bloomfield | M. Cazzola | M. L. Beau | D. Arber | M. Borowitz | J. Vardiman | J. Thiele | R. Hasserjian | A. Orazi | Clara D. Bloomfield | Michael J. Borowitz | J. Vardiman | Mario Cazzola | Jürgen Thiele
[1] T. Barbui,et al. Myeloproliferative neoplasms: Morphology and clinical practice , 2016, American journal of hematology.
[2] A. Tefferi,et al. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia , 2016, Blood Cancer Journal.
[3] T. Walsh,et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia , 2016, Cancer.
[4] H. Gisslinger,et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria , 2015, Leukemia.
[5] P. Valent. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. , 2015, Hematology. American Society of Hematology. Education Program.
[6] S. Barrans,et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. , 2015, Blood.
[7] J. Witte,et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. , 2015, Blood.
[8] F. Fend,et al. Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications , 2015, Modern Pathology.
[9] G. Mufti,et al. An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms , 2015, Haematologica.
[10] W. Evans,et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures , 2015, Haematologica.
[11] T. Barbui,et al. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis , 2015, Blood Cancer Journal.
[12] M. Cazzola,et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene , 2015, Annals of Hematology.
[13] P. Campbell,et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.
[14] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[15] Sa A. Wang,et al. Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities. , 2015, American journal of clinical pathology.
[16] J. Hernández-Rivas,et al. Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts , 2015, PloS one.
[17] R. Hehlmann. CML—where do we stand in 2015? , 2015, Annals of Hematology.
[18] Franco Locatelli,et al. How I treat juvenile myelomonocytic leukemia. , 2015, Blood.
[19] P. Campbell,et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. , 2015, Blood.
[20] P. Campbell,et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.
[21] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[22] M. Loh,et al. T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 , 2014 .
[23] U. Germing,et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. , 2014, Leukemia research.
[24] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[25] J. Radich,et al. Chronic myelogenous leukemia, version 1.2015. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[26] T. Barbui,et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. , 2014, Blood.
[27] Y. Nojima,et al. Philadelphia chromosome‐positive mixed phenotype acute leukemia in the imatinib era , 2014, European journal of haematology.
[28] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[29] B. Bain,et al. Should myeloid and lymphoid neoplasms with PCM1‐JAK2 and other rearrangements of JAK2 be recognized as specific entities? , 2014, British journal of haematology.
[30] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Wade,et al. Outcome for children and young people with Early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2014, British journal of haematology.
[32] R. Bejar. Clinical and genetic predictors of prognosis in myelodysplastic syndromes , 2014, Haematologica.
[33] G. Mufti,et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) , 2014, Haematologica.
[34] D. Birnbaum,et al. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia , 2014, American journal of hematology.
[35] S. Ascani,et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms , 2014, Modern Pathology.
[36] A. Kohlmann,et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% , 2014, Genes, chromosomes & cancer.
[37] P. Campbell,et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes , 2014, Leukemia.
[38] J. Esteve,et al. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1 , 2014, Annals of Hematology.
[39] J. Tchinda,et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome , 2014, Leukemia.
[40] F. Stingo,et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. , 2014, Blood.
[41] J. D. Engel,et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. , 2014, Cancer cell.
[42] Britta A. M. Bouwman,et al. A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia , 2014, Cell.
[43] L. Godley,et al. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations , 2014, Annals of the New York Academy of Sciences.
[44] C. Nakaseko,et al. Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status , 2014, International Journal of Hematology.
[45] T. Barbui,et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms , 2014, Leukemia.
[46] F. Şahin,et al. Granulocytic sarcoma: a systematic review. , 2013, American journal of blood research.
[47] M. Ehinger,et al. World Health Organization‐defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations—The Danish experience , 2013, American journal of hematology.
[48] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[49] T. Barbui,et al. Masked polycythemia Vera (mPV): Results of an international study , 2018, American journal of hematology.
[50] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[51] S. Miyano,et al. The landscape of somatic mutations in Down syndrome–related myeloid disorders , 2013, Nature Genetics.
[52] M. Loh,et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. Mullighan,et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] L. Bullinger,et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. , 2013, Blood.
[55] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[56] D. Birnbaum,et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] L. Arenillas,et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations , 2013, British journal of haematology.
[58] S. Bohlander,et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. , 2013, Blood.
[59] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[60] Angela G. Fleischman,et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. , 2013, The New England journal of medicine.
[61] R. Hills,et al. Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist? , 2013, British journal of haematology.
[62] R. Warnke,et al. Indolent T-Lymphoblastic Proliferation (iT-LBP): A Review of Clinical and Pathologic Features and Distinction from Malignant T-Lymphoblastic Lymphoma , 2013, Advances in anatomic pathology.
[63] C Haferlach,et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations , 2013, Leukemia.
[64] L. Arenillas,et al. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes , 2013, Haematologica.
[65] E. Estey,et al. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. , 2013, Blood.
[66] R. Kralovics,et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.
[67] T. Haferlach,et al. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 , 2013, Annals of Hematology.
[68] F. Fend,et al. Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease , 2013, Modern Pathology.
[69] E. Thiel,et al. FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors , 2013, PloS one.
[70] Robert Huether,et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.
[71] M. Cazzola,et al. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. , 2013, Blood.
[72] Roberta Spinelli,et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia , 2012, Nature Genetics.
[73] A. Kohlmann,et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics , 2013, Leukemia.
[74] D. Neuberg,et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[76] Guido Marcucci,et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Ryan D. Morin,et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.
[78] P. Vyas,et al. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. , 2012, Seminars in fetal & neonatal medicine.
[79] L. Medeiros,et al. Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML , 2012, PloS one.
[80] M. Konopleva,et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia , 2012, Leukemia & lymphoma.
[81] U. Germing,et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. , 2012, Leukemia research.
[82] A. Kohlmann,et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. , 2012, Blood.
[83] Gerhard Ehninger,et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors , 2012, Haematologica.
[84] G. Barosi,et al. Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis , 2012, PloS one.
[85] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[86] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] D. Campana,et al. Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15 , 2012, British journal of haematology.
[88] Kiran C. Bobba,et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.
[89] A. Tefferi,et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. , 2011, Blood.
[90] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[91] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[92] A. Porwit,et al. Acute myeloid leukemia with expanded erythropoiesis , 2011, Haematologica.
[93] T. Barbui,et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[95] H. Gisslinger,et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. , 2011, Blood.
[96] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] Verena I Gaidzik,et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] T. Haferlach,et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. , 2011, Blood.
[99] J. Esteve,et al. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. , 2010, Blood.
[100] J. Meijerink. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. , 2010, Best practice & research. Clinical haematology.
[101] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[102] R. Hills,et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] G. Ossenkoppele,et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification , 2010, Leukemia.
[104] Paola Fazi,et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.
[105] S. Corti,et al. RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant , 2010, Clinical Cancer Research.
[106] H. Kantarjian,et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. , 2010, Blood.
[107] Chieh-Yu Liu,et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.
[108] A. Kohlmann,et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.
[109] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[110] H. Tien,et al. Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’ , 2009, British Journal of Cancer.
[111] Bas J. Wouters,et al. Brief Report Results and Discussion , 2022 .
[112] T. Pabst,et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.
[113] Cheng Cheng,et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.
[114] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[115] Christopher B. Miller,et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.
[116] J. Merker,et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. , 2008, Blood.
[117] U. Germing,et al. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features , 2008, Leukemia.
[118] A. Hagemeijer,et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification , 2007, Leukemia.
[119] K. Lennert,et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.
[120] J. Buckley,et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.
[121] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .
[122] C. Stiller,et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. , 1995, Blood.
[123] R. Gale,et al. Chronic myeloid leukemia. , 1992, The American journal of medicine.
[124] P. Sharma,et al. Inherited Mutations in Cancer Susceptibility Genes Are Common Among Survivors of Breast Cancer Who Develop Therapy-Related Leukemia , 2016 .
[125] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[126] W. Evans,et al. BCR-ABL 1-like cases in pediatric acute lymphoblastic leukemia : a comparison between DCOG / Erasmus MC and COG / St , 2015 .
[127] M. Deininger. Diagnosing and managing advanced chronic myeloid leukemia. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[128] E. Jabbour,et al. CME Information: Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management , 2014 .
[129] U. Germing,et al. Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. , 2013, Leukemia research.
[130] P. Font,et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification , 2012, Annals of Hematology.
[131] R. Schlenk,et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.
[132] R. Pieters,et al. University of Groningen Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia Hollink, , 2011 .
[133] A. Órfão,et al. Mixed phenotype acute leukemia (MPAL): clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification Authors: , 2011 .
[134] C. Steidl,et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.
[135] R. Arceci. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia , 2010 .